O pioid use disorders in America have increased at an alarming rate during the past decade. Among pregnant women aged 15e44 years, 5.4% admitted to currently using illicit drugs, with the highest rates during the first (9%) and second (4.8%) trimester compared with the third (2.4%) trimester. 1 Untreated substance use during pregnancy not only increases maternal pregnancy complications but also increases fetal risk. Specifically, untreated chronic heroin use is associated with an increased risk of pregnancy complications, such as fetal growth restriction, placental abruption, fetal death, preterm labor, third-trimester bleeding, fetal distress, meconium aspiration, and puerperal morbidity.
2,3
Currently methadone is most often prescribed as first-line pharmacotherapy for a pregnant woman with opioid use disorders, but buprenorphine use has increased, 3 as recent evidence suggests comparable efficacy and less severe neonatal complications with buprenorphine compared with methadone. 4 Dosing of buprenorphine is based mostly on expert panel recommendations and subjective data collected from the patient and is dose adjusted using patient symptoms of withdrawal.
Despite such recommendations, there is a lack of consensus concerning appropriate induction and maintenance dosing, monitoring parameters, and duration of therapy because of a wide range of clinical and contextual factors and concerns about diversion. 5 Buprenorphine is extremely lipophilic, highly bound to plasma proteins, and mainly metabolized by cytochrome P450 enzyme superfamily (CYP3A4) and glucuronosyltransferase enzyme superfamily (UGT1A/2B). 6 Pregnancy can substantially alter drug absorption, distribution, metabolism, and/or elimination, possibly leading to changes in the most effective dose or dosing regimen that should be used in this specific patient population. 7 The current investigation examined the pharmacokinetics (PK) of 
Materials and Methods Participants
Women (n ¼ 17) were recruited from Magee-Womens Hospital (Pittsburgh, PA) and an outlying clinic. Participants were recruited and enrolled from June 1, 2014, through Nov. 30, 2014. All participants were receiving twice-daily buprenorphine maintenance therapy, as prescribed for clinical purposes by their respective caregivers, and were expected to be at steady state on their current dose prior to each study visit. The protocol was approved by the University of Pittsburgh's Institutional Review Board, and all participants underwent the informed consent process using institutional review board-approved consent documents.
Procedures
Demographic details, baseline laboratory parameters, medication, and/or substance use history and obstetric history were collected for all participants. Eligibility criteria for these women included the following: (1) pregnant and on a stable, twice-daily dose of buprenorphine for at least 7 days, (2) !18 years of age, (3) able to willingly consent, and (4) willing to have urine samples screened for the presence of alcohol, barbiturates, opiates, cocaine (or metabolites), benzodiazepines, synthetic opioids, PCP, and concurrent medications or substances. Exclusion criteria included the following: (1) hepatic or renal dysfunction, (2) sickle-cell disease and on active treatment, (3) HIV and on active treatment (potential drug interactions), (4) hypersensitivity to opioids, (5) comorbid dependence on benzodiazepines, (6) concurrently taking monoamine oxidase inhibitors, neuroleptics, or disulfiram, and (7) concurrently taking medications known to be CYP3A inducers (such as rifampin, phenobarbital, phenytoin, or carbamazepine) or CYP3A inhibitors (such as azole antifungals, macrolide antibiotics, or HIV protease inhibitors).
Up to 3 studies were performed in each participant. PK-2 studies were performed in the second trimester between 18 and 25 weeks (n ¼ 7), PK-3 studies were performed in the third trimester between 31 and 37 weeks (n ¼ 11), and PK-P was performed 4-18 weeks postpartum (n ¼ 10). All PK study visits were identical and conducted in the Clinical and Translational Research Center of the University of Pittsburgh Medical Center's Montefiore Hospital.
Participants arrived early in the morning after a !8 hour fast with their medication log, underwent a predose blood draw (BD Vacutainer glass blood collection tubes with sodium heparin; Becton Dickson Inc, Franklin Lakes, NJ) and oral fluid collection (Sarstedt salivette cotton swab for saliva collection; Sarstedt Inc, Newton, NC) for trough buprenorphine concentrations and clinical laboratory parameters; provided a urine sample for laboratory tests and toxicology; had oral pH recorded (Hydrion urine and saliva pH paper, range 5.5e8.0; Micro Essential Lab, Brooklyn, NY); and then took their prescribed sublingual buprenorphine dose under direct supervision by study staff.
Participants were instructed to allow the tablets to dissolve under their tongue, with minimal swallowing, until there was no visible residue remaining. Dissolution time was recorded after visual inspection of the sublingual area by study staff. Serial blood and oral fluid samples were subsequently collected over 1 dosing interval at 0 (before the dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, 10, and 12 hours after the dose. All blood samples and oral fluid salivettes were centrifuged for 15 minutes at 15,000 rpm to obtain plasma and oral fluid, respectively. Samples were immediately frozen at e80 C until analysis.
All spontaneously voided urine was collected throughout the entire study period of 12 hours. Participants were not allowed to eat until 2 hours after the dose to allow for adequate drug absorption, and all food consumed during the study day was reported on a dietary log.
Assay methodology
Buprenorphine (BUP) and its 3 active metabolites (norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide), along with the deuterated internal standards for BUP, norbuprenorphine, and norbuprenorphine glucuronide (buprenorphine glucuronide was not available), were extracted from plasma samples by solid-phase extraction methods.
Plasma concentrations were determined using high-performance liquid chromatography with tandem mass spectrometric detection. The peaks of interest were well separated and the overall run time for each sample was 7 minutes. Detection was accomplished utilizing ion spray tandem mass spectrometry in positive ion multiple reaction monitoring mode. The lower limit of quantification was 0.05 ng/mL for BUP, and calibration curves were linear, ranging from 0.05 to 50 ng/mL for BUP with coefficients of determination (r2) greater than 0.99.
Both the intraday and interday precisions were evaluated and the coefficient of variation values were less than 15% for low, medium, and high controls. The accuracy as measured by bias was less than 5%. Cumulative urine and serial oral fluid samples were also collected and concentrations measured (data not shown).
Statistical analysis
Noncompartmental analysis was performed and various PK parameters were calculated using Microsoft Excel (Richmond, WA). Maximum BUP plasma concentrations (Cmax), trough BUP concentrations at time zero (C0), BUP concentrations at 12 hours (C12), and time to maximum BUP concentrations (Tmax) were observed values using each participant's plasma concentrationtime profile.
In each of the participants, the area under the BUP plasma concentrationtime curve for the 12 hour dosing interval (AUC 0/12 ) was calculated from time 0 to 12 hours using the trapezoidal rule.
The mean values were then used to compare cohorts. Given the reportedly long half-life of buprenorphine (approximately 37 hours) 7 and the ajog.org
shorter dosing interval (12 hours) used in the study participants, it was not possible to calculate the terminal half-life. Univariate descriptive statistics were used to summarize sample demographic and clinical characteristics at each study visit. Means and standard deviations were reported for continuous variables, and frequencies and percentages were reported for categorical variables. BUP pharmacokinetic data were similarly summarized descriptively at each study visit using means and standard deviations. Statistical analyses were then performed to identify significant differences in BUP PK parameters between (1) PK-2 and PK-3 and (2) pregnancy and postpartum, without focus on a specific trimester of pregnancy.
The distributions of sample PK data were investigated, and a natural logarithmic transformation was applied to each of the PK variables to produce approximately normally distributed data for statistical analysis. Univariate linear mixed models were then fit to the logtransformed PK data to make the 2 comparisons of interest because such modeling techniques utilize data from every participant and do not require that participants have complete data at all 3 study visits.
Time (PK-2, PK-3, and PK-P) was treated as a categorical fixed effect in all models, and a random effect was included in the models to account for repeated measures over time from the same participants. For the random effect of time, a variance component covariance structure was assumed. Models were fit through maximum likelihood estimation in SAS version 9.4 (SAS Institute, Cary, NC), and convergence criteria were met without problems.
The fitted models were then used to compare PK parameters between the second and third trimesters as well as between pregnancy and postpartum, using Student t tests. Specifically, the first comparison tested whether the logtransformed PK parameter differed significantly between PK-2 and PK-3. For the second comparison, a formal hypothesis test was performed to determine whether the log-transformed mean at PK-P differed significantly from the average of the log-transformed means at PK-2 and PK-3. The 2 P values were adjusted for multiple comparisons using the Sidak adjustment method. A value of P <.05 indicated a statistically significant difference.
Results
Seventeen participants provided informed consent for the study. Two participants were excluded after baseline assessment: one for a failed urine comprehensive drug screen and one for an ectopic pregnancy. One participant was lost to follow-up after consent and was never screened. Thus, data from 14 pregnant women were available for pharmacokinetic analysis, and 6 of these 14 participants were studied at all 3 time points.
Among these 14 participants, a total of 35 pharmacokinetic studies were completed: 9 in PK-2, 13 in PK-3, and 13 in PK-P. Of these 35 studies, 7 were deemed invalid: 2 participants' data were excluded from the PK-2 analysis, and 2 participants' data were excluded from PK-3 analysis because the buprenorphine concentration at time 0 was significantly higher than the buprenorphine concentration at 12 hours, indicating participants had an atypical concentration-time profile and were likely not adherent to a 12 hour dosing interval.
Data from 2 participants were excluded from the PK-P analysis because they were switched by their providers to Suboxone film (buprenorphine/ naloxone) at the time of the study, which may have different pharmacokinetic characteristics than sublingual buprenorphine tablets. Data from 1 participant was also excluded from the PK-P analysis after her medication log showed once-daily rather than twice-daily buprenorphine dosing.
This resulted in 28 studies with pharmacokinetic data being available for further analysis (18 from the 6 participants who were studied at all 3 time points): 7 for PK-2, 11 for PK-3, and 10 for PK-P.
The characteristics of the study participants are listed in Table 1 according to the time of study. The mean gestational ages were 22.0 weeks for PK-2 and 33.9 weeks for PK-3. The PK-P study was performed at a mean of 7.4 weeks after delivery. All but 1 participant studied postpartum (PK-P) was also studied at least once in pregnancy (PK-2 or PK-3 or both). The PK parameter estimates are summarized in Table 2 . During pregnancy (average of PK-2 plus PK-3), the dose-normalized (plasma concentration/dose) area under the BUP plasma concentration-time curves (AUC 0/12 ) and Cmax BUP concentrations, as well as the BUP concentrations at 0 and 12 hours were significantly lower than during the postpartum period. None of these parameters differed significantly during pregnancy (ie, PK-2 vs PK-3). The Tmax BUP concentrations did not differ significantly between groups. Figure 1 demonstrates the dosenormalized (plasma concentration/dose) average BUP plasma concentration-time curves (mean AE SD) over the 12 hour study in all participants (PK-2, n ¼ 7; PK-3, n ¼ 11; PK-P, n ¼ 10). Plasma concentrations rise rapidly in all study groups, start approaching trough (C0) concentrations by 4-6 hours, and nearly reach baseline values by 8 hours after drug administration.
There is considerable variability in all groups, yet the mean buprenorphine plasma concentrations differed significantly between pregnancy and postpartum as well as between the third trimester and postpartum (ie, PK-3 and PK-P). Figure 2 relates the raw trough plasma concentrations of buprenorphine to the AUC 0/12 from all 28 studies.
There is a strong correlation (coefficient of determination, r2 ¼ 0.87) between the trough concentration just prior to a dose (C0) and exposure (AUC 0/12 ) over the ensuing 12 hours. area under the plasma concentration time curve over the ensuing 12 hours. This relationship indicates that a single plasma sample concentration measurement prior to the next dose may be a surrogate marker of Data are presented as mean AE SD (raw and untransformed). P value columns represent comparisons between the following: (i) second vs third trimester, PK-2 vs PK-3; and (ii) pregnancy vs postpartum, the average of PK-2 and PK-3 vs PK-P. 
FIGURE 1
Dose-normalized buprenorphine plasma concentrations during pregnancy and postpartum
The mean dose-normalized buprenorphine plasma concentration-time curves (AESD) during the 12 hour pharmacokinetic study visits: PK-1a (n ¼ 7), PK-1b (n ¼ 11), and PK-2 (n ¼ 10). The X axis is the time in hours; the Y axis is the mean dose-normalized buprenorphine plasma concentrations in nanograms per milliliter per milligram of buprenorphine.
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OBSTETRICS Original Research buprenorphine exposure in participants on a fixed dose and dosing regimen (the coefficient of determination is 0.57 when the 2 outliers are removed). The average oral pH for all participants were as follows (mean AE SD): PK-2, 6.2 AE 0.44; PK-3, 6.4 AE 0.67; PK-P, 6.5 AE 0.71, as measured by salivary pH strips. There was no correlation between oral pH and dissolution time, AUC 0/12 , Cmax, or Tmax in any of the 3 groups (data not shown).
Comment
This study demonstrates that dosenormalized exposure (AUC 0/12 ) to buprenorphine following sublingual administration was approximately 50% lower during pregnancy compared with the postpartum period. These findings are consistent with the study of Concheiro et al, 8 who reported similar findings in their study of 3 pregnant women (1 with twin gestation). Our larger sample size and restriction to singleton gestation, however, allowed for more meaningful comparisons between pregnancy and the postpartum state.
Our findings are not unexpected, given the physiological changes associated with pregnancy and the specific pharmacological characteristics of buprenorphine, which may have an impact on the absorption, distribution, metabolism, and/or elimination of this medication throughout gestation.
The major contributor to the differences in buprenorphine exposure between pregnant and postpartum women is predicted to be changes in metabolism. Buprenorphine is cleared from the body through metabolism that involves CYP3A and UGT enzymes. 9 The activity of CYP3A, the primary enzyme responsible for the metabolism of buprenorphine to norbuprenorphine, has been shown to be significantly increased during pregnancy. Buprenorphine and norbuprenorphine are conjugated to their respective glucuronide metabolites by UGT1A1, UGT1A3, and UGT2B7. Activity of glucuronide conjugating enzymes has also been shown to increase during pregnancy (specifically UGT1A and UGT2B enzymes). 10 Buprenorphine is a small, very lipophilic compound (log P ¼ 4.98) that is highly bound to plasma proteins (percentage bound, 98%). 9 In pregnancy, protein levels decrease and maternal body fat increases, leading to a larger volume of distribution for drugs like buprenorphine.
11 This is consistent with our observation of a significant decrease in Cmax during both PK-PK-2 and PK-PK-3 as compared with PK-PK-P as well as significant differences in protein levels and body weights of the study participants in each cohort.
The absorption and dissolution of sublingual buprenorphine could be affected by salivary pH, which generally decreases in pregnancy. 12 A low salivary pH can reduce absorption because less of the drug would be unionized, and this could contribute to a smaller area under the curve during pregnancy. In our population, salivary pH did not differ between groups and therefore was not correlated with changes in AUC 0/12 , Cmax, Tmax, or dissolution time.
Absorption may also be influenced by pill size. Many participants in the current study chose to break up the sublingual buprenorphine tablet(s) into smaller pieces for convenience and comfortable placement in the sublingual area as well as for taste-masking purposes to limit nausea while allowing the tablet(s) to dissolve. We did not control for this at the time of the study, which may account for some of the variation in plasma concentrations. However, this is also unlikely to account for the changes observed because a recent publication did not demonstrate significant differences in dissolution or absorption time between crushed and whole buprenorphine tablets. 13 The clinical implications of the pharmacological findings of this study relate primarily to the dosing of buprenorphine during pregnancy. Dosing of buprenorphine during pregnancy is generally based on data from nonpregnant adults. This approach has repeatedly been shown to lead to errors in dosing pregnant women with a variety of medications. 14 Depending on the specific pharmacokinetic properties of the drug in question, either plasma concentrations are too high, leading to potential side effects, or plasma concentrations are too low, leading to possible treatment failure. Such considerations have not been adequately incorporated into the dosing of buprenorphine for pregnant women.
The failure rate during the induction period with buprenorphine has been reported to be as high as 33% in pregnant participants, 4 and it is conceivable that some of these failures are due to inadequate buprenorphine plasma concentrations. Indeed, our data indicate that buprenorphine is cleared more extensively by pregnant than postpartum women. An inadequate dose may contribute both to abandonment of buprenorphine during the induction phase and continued illegal substance use during the stabilization and maintenance phases.
The 2015 recommendations by the Substance Abuse and Mental Health Services Administration did not recommend specific dosing strategies for pregnant women but rather refer to the package insert to determine the dose of buprenorphine.
15 Unfortunately, the Food and Drug Administratione approved monograph does not distinguish dosing for pregnant women from dosing for nonpregnant individuals. A total daily dose of 8e16 mg is suggested during induction. To minimize dropout, the package insert suggests that the dose be "rapidly titrated to achieve clinical effectiveness" during the stabilization phase.
This strategy of dosing to response, which recent literature shows may be between 16 and 24 mg per day for clinical effectiveness, 16 is reasonable for pregnancy but since higher doses may be needed in pregnant women, implementation of this strategy could lead to obstacles. First, some insurers will only reimburse for doses up to 16 mg daily without peer review by an insurance intermediary, usually a physician but not necessarily an expert in drug addiction or obstetrical pharmacokinetics. The patient's care provider is then obligated to explain why a higher dose is needed and justification may prove challenging.
These not so subtle policies serve as an impediment to optimal care during pregnancy, when the risk of neonatal abstinence syndrome from continued use of illegal opioids far outweighs insurance limits. Second, a need for a higher dose also raises the question of diversion both in the minds of the care provider and the insurance representative, yet our data provide prescribers the support they need to titrate to clinical effectiveness without fear of legal repercussions. Hopefully our data will serve as evidence to policy makers, insurers, and physicians alike that pregnant women may need higher doses of buprenorphine compared with nonpregnant adults simply because of the pregnancy-associated physiological changes that directly affect the pharmacokinetic properties of buprenorphine.
It is not clear from the present study at what time during pregnancy the more extensive clearance of buprenorphine occurs. Because many pregnant women undergo conversion to buprenorphine in the first half of pregnancy, it is important to determine when and how often dosing adjustments should be made during and after pregnancy, for both the prescriber's benefit and that of the maternal-fetal dyad. n
